Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2018

View Archived Issues

Pfizer enrolling patients in phase II study of PF-06823859 in moderate to severe dermatomyositis

PharmAbcine, MSD to evaluate TTAC-0001 with Keytruda

FDA awards rare pediatric disease designation to MeiraGTx's A-002

Starpharma receives approval to initiate phase I/II study of DEP cabazitaxel

Daiichi Sankyo reviews highlights of third quarter of fiscal 2017

Avelumab shows clinical activity in patients with previously treated mesothelioma

Phase II data on RX-3117 shows promise for pancreatic cancer treatment

UCB announces launch of Syndesi Therapeutics to develop therapeutics for cognitive disorders

Vical enters collaboration to advance candidate for invasive aspergillosis

FDA approves Avycaz for hospital-acquired and ventilator-associated bacterial pneumonias

Anika Therapeutics collaborates with University of Liverpool on MSC therapy for osteoarthritis

FDA grants priority review to patisiran NDA in hereditary ATTR amyloidosis

AVROBIO completes series B financing to advance gene therapy pipeline for lysosomal storage disorder

Sage Therapeutics presents new GABA(A) receptor modulators

CANbridge Life Sciences licenses rights to Nerlynx in Greater China

Medshine Discovery patents novel S1P1 agonists

Phase II/III Japanese study of safinamide meets primary endpoint

Aduro BioTech and Novartis patent STING-agonists

Crinetics Pharmaceuticals identifies new somatostatin SST2 receptor agonists

Syndax and AstraZeneca to test durvalumab plus SNDX-6352 in solid tumors

Roche presents new compounds for HBV

Japanese submission seeks approval of Ventana OptiView ALK as companion diagnostic for Alecensa

Affimed reveals new data from clinical studies of AFM-13

Veliparib combined with oxaliplatin and capecitabine proven safe in solid cancers

Five-year D-CARE trial of denosumab in breast cancer misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...